跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 20,775 条关于
“metabolic dysfunction steatohepatitis”
全部
20,775
临床试验
17,114
药物
139
机构
49
资讯
3,473
2年前
Madrigal's Resmetirom Nears Full Approval for NASH Cirrhosis Treatment Following Phase 3 Enrollment Completion
去年
AI-Based Pathology Tool Validated for Scoring Metabolic Dysfunction-Associated Steatohepatitis
去年
Multi-biotics Enhance Lenvatinib Sensitivity in MASH-Related HCC Organoids
去年
Wegovy Shows Promise in Treating MASH with Advanced Liver Fibrosis
去年
Sagimet's Denifanstat Receives FDA Breakthrough Therapy Designation for MASH
去年
Sagimet Biosciences to Present Denifanstat's Anti-Fibrotic Effects in MASH at MASH-TAG 2025
去年
Sagimet's Denifanstat Receives FDA Breakthrough Therapy Designation for MASH
去年
EMA Endorses AI-Powered Pathology Tool to Enhance MASH Clinical Trial Accuracy
7年前
FDA Approves Resmetirom (Rezdiffra) for Treating MASH and Associated Fibrosis
去年
Lanifibranor Shows Promise in MASH Patients with Type 2 Diabetes: LEGEND Trial Results
第 1 页，共 348 页
上一页
下一页
